share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股SEC公告 ·  06/05 12:31

Moomoo AI 已提取核心訊息

Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 50,000 Class A shares of the company, with an aggregate market value of $421,000, on 06/05/2024. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned transaction follows a series of sales over the past three months, where Gibson sold a total of 356,319 shares, amounting to gross proceeds of approximately $3.35 million.
Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 50,000 Class A shares of the company, with an aggregate market value of $421,000, on 06/05/2024. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned transaction follows a series of sales over the past three months, where Gibson sold a total of 356,319 shares, amounting to gross proceeds of approximately $3.35 million.
Recursion Pharmaceuticals董事暨高級職員Christopher Gibson預計於2024年6月5日賣出該公司5萬股A類股,市值共計42.1萬美元。這些股票是於2016年1月9日獲得的創始股份,是發行人的一種補償形式。此次預計交易是在過去三個月中一系列出售的基礎上進行的,Gibson總共出售了356,319股,總收益約335萬美元。
Recursion Pharmaceuticals董事暨高級職員Christopher Gibson預計於2024年6月5日賣出該公司5萬股A類股,市值共計42.1萬美元。這些股票是於2016年1月9日獲得的創始股份,是發行人的一種補償形式。此次預計交易是在過去三個月中一系列出售的基礎上進行的,Gibson總共出售了356,319股,總收益約335萬美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息